BioSpace News Archive

“Live with no regrets, but reserve the right to change your mind.” This is how millions of Americans feel about their tattoos. Over the past decade, demand for tattoo removal has grown rapidly. Top reasons consumers report wanting to remove tattoos are feelings that they were too young when they received the tattoo, that their personalities have changed and tattoos no longer fit their lifestyle, and that they wish to erase the names of former boyfriends and girlfriends.

Onclive the leading digital provider of resources and information to oncology professionals, will host the latest State of the Science Summit on treatment of hematologic malignancies.

Technavio has announced their latest drug pipeline analysis report on nosocomial pneumonia. The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of nosocomial pneumonia.

The Hazelden Betty Ford Foundation today announced plans to expand into the Seattle area with a new addiction treatment center in Bellevue, Wash.

Monte Nido & Affiliates announces the opening of Clementine, the newest eating disorder treatment center exclusively for adolescent girls aged twelve to seventeen in Fairfax County, Virginia. Clementine will debut its newest residential treatment center this October.

NxGen MDx announced a new partnership with Answer Health on Demand, which enables patients to see a genetic counselor or doctor using secure audio and video via smartphone application, tablet, or computer.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C. Greiner, Executive Vice President and Chief Financial Officer, will present at the Cantor Global Healthcare Conference at 8:35 a.m. ET on Tuesday, October 2, 2018 in New York, NY.

Pulse Biosciences, Inc. announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 34,250 shares of Pulse Biosciences common stock to four new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on September 17, 2018.

Dr. Parker will also assist with business development for the Prisyna oral care division of Synedgen.

APTIOM provides an important new treatment option for adolescents and children above six years of age with partial-onset seizures